Journal
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Volume 181, Issue -, Pages -Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.critrevonc.2022.103886
Keywords
Head and neck cancer; Salivary gland cancer; Oncology; Chemotherapy
Categories
Ask authors/readers for more resources
Adenoid cystic carcinoma (ACC) has a significant patient population that lacks effective systemic therapy. We reviewed ACC clinical trials on ClinicalTrials.gov and found that most trials were one-arm phase II trials enrolling advanced, recurrent/metastatic, incurable ACC cases. Small-molecule inhibitors, such as Apatinib, Axitinib, and Lenvatinib, showed promising results. However, more efforts are urgently needed in this field to improve the overall median time to progression.
Adenoid cystic carcinoma (ACC) has a significant patient-population in need of effective systemic therapy, as no drug is currently approved by the FDA for its management. We critically reviewed ACC-clinical trials (CT) registered on the ClinicalTrials.gov website using ACC under condition or disease. Trials specifically designed to test a drug-based therapy for ACC (n = 33) were analyzed with most being one-arm phase II trials enrolling advanced, recurrent/metastatic, incurable ACC cases. Site restriction, maximum ECOG status, and period of disease progression varied as inclusion criteria. Small-molecule inhibitors were those most commonly investi-gated with Apatinib, Axitinib and Lenvatinib showing the best results in association with rigid enrollment criteria. The overall median time to progression remains modest and more efforts are urgently needed in this field. CTs designed to test drugs that act on key pathways associated with ACC aggressiveness are being con-ducted and represent a promising pathway if efficacy is proved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available